Evidence map›Paper›PMID 35649962›Full record

ReviewProgress in retinal and eye research2022

Corneal stromal repair and regeneration.

Rajiv R Mohan, Duraisamy Kempuraj, Sharon D'Souza, Arkasubhra Ghosh

Open access · greenAbstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
22.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rajiv R MohanHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States; Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO, United States. Electronic address: mohanr@health.missouri.edu.
Duraisamy KempurajHarry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Sharon D'SouzaDepartment of Cornea and Refractive Surgery, Narayana Nethralaya, Bangalore, Karnatka, India.
Arkasubhra GhoshGROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnatka, India.
Missouri College · USNarayana Nethralaya · IN

Funding

Gene Therapy in the CorneaR01EY017294 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2007 to 2018
$4.3M
Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur MustardU01EY031650 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2020 to 2024
$3.7M
Novel approaches for corneal haze/fibrosis eliminationR01EY030774 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2019 to 2022
$1.5M
Hydrogen sulfide toxicity to the corneaR21EY032742 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2021 to 2022
$428k
BLRD VA I01 BX000357BLRD VA IK6 BX005646NEI NIH HHS R01 EY017294NEI NIH HHS R01 EY030774NEI NIH HHS R21 EY032742NEI NIH HHS U01 EY031650
6 · The paper itself

Abstract

The cornea is a specialized, transparent, avascular, immune-privileged, and heavily innervated tissue that affords 2/3rd of refraction to the eye. Ocular injuries, infections, and genetic factors affect corneal function and cause vision impairment. Presently, a variety of laser/non-laser surgeries, immunosuppressants, and/or corneal transplants are predominantly used to revive sight in human patients. The development of novel, precision-guided, and tissue-targeted non-surgical therapies promoting corneal repair and regeneration based on mechanistic understanding is of paramount importance to reduce the impact of global blindness. Research over the past decade revealed that modulation of pathological signaling pathways and factors by a variety of therapeutic delivery methods effectively treats corneal disorders including corneal scar/haze, inflammation, and angiogenesis in various pre-clinical animal models and are primed for human translation. This review discusses recent advances in the areas of corneal repair, restoration, and regeneration. Herein, we provide an overview of evolving approaches and therapeutic modalities that have shown great promise in reviving corneal transparency and function through the use of small drug molecules, gene therapy, nanomedicine, stem cells, trophic factors, exosomes, stromal equivalents, bioengineered stromal scaffolds, tissue adhesives, and 3D bioprinting.

Indexed as

Corneal InjuriesCorneal TransplantationAnimalsCorneaCorneal StromaHumansRefraction, OcularRegenerationWound HealingCorneaCorneal gene therapyCorneal wound healingEmerging therapiesKeratocytesStromal regenerationStromal remodeling

Identifiers

PMID35649962
PMCPMC11926992
OpenAlexW4281985799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.